Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 63 articles:
HTML format
Text format



Single Articles


    November 2017
  1. PENG F, Wang JH, Fan WJ, Meng YT, et al
    Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia.
    Oncogene. 2017 Nov 6. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    October 2017
  2. LANGER EM, Kendsersky ND, Daniel CJ, Kuziel GM, et al
    ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells.
    Oncogene. 2017 Oct 30. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  3. KNOPFOVA L, Biglieri E, Volodko N, Masarik M, et al
    Transcription factor c-Myb inhibits breast cancer lung metastasis by suppression of tumor cell seeding.
    Oncogene. 2017 Oct 30. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  4. LUCANUS AJ, Yip GW
    Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  5. WANG CH, Wang PJ, Hsieh YC, Lo S, et al
    Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties.
    Oncogene. 2017 Oct 9. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    September 2017
  6. XIA L, Xiao X, Liu WL, Song Y, et al
    Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFbeta signaling.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  7. YAMAGUCHI H, Du Y, Nakai K, Ding M, et al
    EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  8. ROWSON-HODEL AR, Wald JH, Hatakeyama J, O'Neal WK, et al
    Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.
    Oncogene. 2017 Sep 11. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    August 2017
  9. KIM ES, Kim SY, Koh M, Lee HM, et al
    C-reactive protein binds to integrin alpha2 and Fcgamma receptor I, leading to breast cell adhesion and breast cancer progression.
    Oncogene. 2017 Aug 28. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  10. SU CM, Wang MY, Hong CC, Chen HA, et al
    miR-520h is crucial for DAPK2 regulation and breast cancer progression.
    Oncogene. 2017 Aug 21. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  11. WADA M, Canals D, Adada M, Coant N, et al
    P38 delta MAPK promotes breast cancer progression and lung metastasis by enhancing cell proliferation and cell detachment.
    Oncogene. 2017 Aug 7. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    July 2017
  12. HEILMANN K, Toth R, Bossmann C, Klimo K, et al
    Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  13. PETERS AA, Jamaludin SYN, Yapa KTDS, Chalmers S, et al
    Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  14. GALLAGHER EJ, Zelenko Z, Neel BA, Antoniou IM, et al
    Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  15. FETTIG LM, McGinn O, Finlay-Schultz J, LaBarbera DV, et al
    Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.
    Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    June 2017
  16. HERNANDEZ-PEREZ S, Cabrera E, Salido E, Lim M, et al
    DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
    Oncogene. 2017 Jun 26. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  17. TANG X, Ding CK, Wu J, Sjol J, et al
    Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.
    Oncogene. 2017 Jun 12. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  18. SENGUPTA S, Nagalingam A, Muniraj N, Bonner MY, et al
    Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  19. SHAHI P, Wang CY, Chou J, Hagerling C, et al
    GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    April 2017
  20. JALAGUIER S, Teyssier C, Nait Achour T, Lucas A, et al
    Complex regulation of LCoR signaling in breast cancer cells.
    Oncogene. 2017 Apr 17. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  21. CHEN Y, Zeng C, Zhan Y, Wang H, et al
    Aberrant low expression of p85alpha in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  22. COHEN N, Shani O, Raz Y, Sharon Y, et al
    Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    March 2017
  23. THEWES V, Simon R, Hlevnjak M, Schlotter M, et al
    The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERalpha-negative breast cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  24. FOO TK, Tischkowitz M, Simhadri S, Boshari T, et al
    Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  25. HERNANDEZ-PEREZ S, Cabrera E, Salido E, Lim M, et al
    DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  26. YU L, Di Y, Xin L, Ren Y, et al
    SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGFbeta1 response and breast cancer metastasis.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    February 2017
  27. WU MJ, Kim MR, Chen YS, Yang JY, et al
    Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKCzeta pathway.
    Oncogene. 2017 Feb 20. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  28. LIN C, Liao W, Jian Y, Peng Y, et al
    CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    January 2017
  29. JHAN JR, Andrechek ER
    Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis.
    Oncogene. 2017 Jan 30. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  30. HE Y, Northey JJ, Pelletier A, Kos Z, et al
    The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.
    Oncogene. 2017 Jan 30. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  31. YANG N, Wang C, Wang Z, Zona S, et al
    FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.
    Oncogene. 2017 Jan 23. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  32. CRISTOBAL I, Zazo S, Torrejon B, Pedregal M, et al
    CIP2A confirms its prognostic value in triple-negative breast cancer.
    Oncogene. 2017 Jan 9. doi: 10.1038/onc.2016.
    PubMed     Text format    


  33. ZHOU H, Liu Y, Zhu R, Ding F, et al
    FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.
    Oncogene. 2017 Jan 9. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    November 2016
  34. FENG J, Li L, Zhang N, Liu J, et al
    Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.
    Oncogene. 2016 Nov 28. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  35. YU L, Liang Y, Cao X, Wang X, et al
    Identification of MYST3 as a novel epigenetic activator of ERalpha frequently amplified in breast cancer.
    Oncogene. 2016 Nov 28. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  36. HIKEN JF, McDonald JI, Decker KF, Sanchez C, et al
    Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  37. TANG X, Ding CK, Wu J, Sjol J, et al
    Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    October 2016
  38. BLOMME A, Costanza B, de Tullio P, Thiry M, et al
    Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer.
    Oncogene. 2016 Oct 24. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  39. YANG C, Li Z, Bhatt T, Dickler M, et al
    Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
    Oncogene. 2016 Oct 17. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  40. HARROD A, Fulton J, Nguyen VT, Periyasamy M, et al
    Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.
    Oncogene. 2016 Oct 17. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  41. MIMOTO R, Imawari Y, Hirooka S, Takeyama H, et al
    Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  42. LONE MU, Baghel KS, Kanchan RK, Shrivastava R, et al
    Physical interaction of estrogen receptor with MnSOD: implication in mitochondrial O2.- upregulation and mTORC2 potentiation in estrogen-responsive breast cancer cells.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  43. LIU H, Qiu H, Song Y, Liu Y, et al
    Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    September 2016
  44. LEFORT S, Thuleau A, Kieffer Y, Sirven P, et al
    CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
    Oncogene. 2016 Sep 26. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  45. YU PF, Huang Y, Xu CL, Lin LY, et al
    Downregulation of CXCL12 in mesenchymal stromal cells by TGFbeta promotes breast cancer metastasis.
    Oncogene. 2016 Sep 26. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  46. KWAK T, Drews-Elger K, Ergonul A, Miller PC, et al
    Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.
    Oncogene. 2016 Sep 26. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  47. CHANG SS, Yamaguchi H, Xia W, Lim SO, et al
    Aurora A kinase activates YAP signaling in triple-negative breast cancer.
    Oncogene. 2016 Sep 5. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  48. KANG MH, Jeong KJ, Kim WY, Lee HJ, et al
    Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.
    Oncogene. 2016 Sep 5. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    August 2016
  49. TOMINAGA K, Shimamura T, Kimura N, Murayama T, et al
    Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells.
    Oncogene. 2016 Aug 22. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  50. XU Y, Qin L, Sun T, Wu H, et al
    Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
    Oncogene. 2016 Aug 15. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    July 2016
  51. YU PF, Huang Y, Han YY, Lin LY, et al
    TNFalpha-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2+ neutrophils.
    Oncogene. 2016 Jul 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  52. SAHA SK, Choi HY, Kim BW, Dayem AA, et al
    KRT19 directly interacts with beta-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties.
    Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  53. XU LZ, Li SS, Zhou W, Kang ZJ, et al
    p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA.
    Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  54. FERRER CM, Lu TY, Bacigalupa ZA, Katsetos CD, et al
    O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway.
    Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  55. WERDEN SJ, Sphyris N, Sarkar TR, Paranjape AN, et al
    Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth.
    Oncogene. 2016 Jun 13. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  56. DA MOTTA LL, Ledaki I, Purshouse K, Haider S, et al
    The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
    Oncogene. 2016 Jun 13. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  57. RAMADOSS S, Guo G, Wang CY
    Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    May 2016
  58. CAO C, Vasilatos SN, Bhargava R, Fine JL, et al
    Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
    Oncogene. 2016 May 23. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  59. FARMAKI E, Chatzistamou I, Kaza V, Kiaris H, et al
    A CCL8 gradient drives breast cancer cell dissemination.
    Oncogene. 2016 May 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  60. HEIN AL, Post CM, Sheinin YM, Lakshmanan I, et al
    RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.
    Oncogene. 2016 May 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  61. MENDOZA-VILLANUEVA D, Balamurugan K, Ali HR, Kim SR, et al
    The C/EBPdelta protein is stabilized by estrogen receptor alpha activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer.
    Oncogene. 2016 May 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  62. TURPIN J, Ling C, Crosby EJ, Hartman ZC, et al
    The ErbB2DeltaEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.
    Oncogene. 2016 May 9. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  63. TEO WW, Merino VF, Cho S, Korangath P, et al
    HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24.
    Oncogene. 2016 May 9. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: